Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial
Anna H Roukens, Ann C Vossen, Peter J Bredenbeek, Jaap T van Dissel, Leo G Visser, Anna H Roukens, Ann C Vossen, Peter J Bredenbeek, Jaap T van Dissel, Leo G Visser
Abstract
Background: Implementation of yellow fever vaccination is currently hampered by limited supply of vaccine. An alternative route of administration with reduced amounts of vaccine but without loss of vaccine efficacy would boost vaccination programmes.
Methods and findings: A randomized, controlled, non-inferiority trial was conducted in a Dutch university center between August 2005 and February 2007. A total of 155 primary vaccinated and 20 previously vaccinated volunteers participated. Participants were randomly assigned in a 1ratio1 ratio to receive intradermal (i.d.) vaccination with live attenuated yellow fever 17D vaccine at a reduced dose (1/5(th); 0.1 mL) or the conventional subcutaneous (s.c.) vaccination (0.5 mL). Antibody neutralization titers were determined at 2, 4 and 8 weeks and 1 year after vaccination by counting the reduction in virus-induced plaques in the presence of serial serum dilutions. Adverse events were documented in a 3-week dairy. Viraemia was measured 5 days after vaccination. From 2 weeks up to one year after vaccination, the maximum serum-dilution at which 80% of the virus plaques were neutralized, which indicates protection against yellow fever, did not differ between those given a reduced i.d. dose or standard s.c. dose of vaccine. In all cases the WHO standard of seroprotection (i.e. 80% virus neutralization) was reached (in 77/77 and 78/78, respectively). Similar results were found in the previously vaccinated individuals. Viraemia was detected in half of the primary vaccinated participants, which was not predictive of serological response. In revaccinees no viraemia was detected.
Conclusions: Intradermal administration of one fifth of the amount of yellow fever vaccine administered subcutaneously results in protective seroimmunity in all volunteers. Albeit this vaccination route should enable vaccination of five-times as many individuals at risk for disease, these results should now be confirmed in field studies in areas with potential yellow fever virus transmission to change vaccination policy.
Trial registration: Nederlands Trial Register ISRCTN46326316.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, et al. Yellow fever: a decade of reemergence. JAMA. 1996;276:1157–1162.
- Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11–20.
- WHO. Weekly epidemiological record. Yellow fever situation in Africa and South America. 2005;81:317–324. . Accessed 10 Oct 2007.
- Roberts L. Infectious disease. Resurgence of yellow fever in Africa prompts a counterattack. Science. 2007;316:1109.
- Monath TP. Yellow Fever. In: Plotkin SA, Orenstein WA, editors. Vaccines. W.B. Saunders Company; 1999. pp. 815–879.
- Monath TP. Stability of yellow fever vaccine. Dev Biol Stand. 1996;87:219–225.
- Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351:2286–2294.
- Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295–2301.
- Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA. 1985;254:3203–3206.
- Warrell MJ, Warrell DA, Suntharasamai P, Viravan C, Sinhaseni A, et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post exposure prophylaxis. Lancet. 1983;2:301–304.
- Fox JP, Luty Kossobudski S, Fonseca da Cunha J. Field studies on the immune response to 17D yellow fever virus. Relation to virus substrain, dose and route of inoculation. The American Journal of Hygiene. 1943;38:113–138.
- Cannon SA, Dewhurst F. Vaccination by scarification with 17D yellow fever vaccine prepared at Yaba, Lagos, Nigeria. Ann Trop Med Parasitol. 1953;47:381–393.
- Dick GW. A preliminary evaluation of the immunizing power of chick-embryo 17 D yellow fever vaccine inoculated by scarification. Am J Hyg. 1952;55:140–153.
- Center for Disease Control, Mantoux Tuberculosis Skin Test Facilitator Guide. (accessed 2nd of August 2007)
- De Madrid AT, Porterfield JS. A simple micro-culture method for the study of group B arboviruses. Bulletin of the World Health Organization. 1969;40:113–121.
- Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1873;25:539–544.
- Nijhuis M, van Maarseveen N, Schuurman R, Verkuijlen S, de Vos M, et al. Rapid and sensitive routine detection of all members of the genus enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol. 2002;40:3666–3670.
- Drosten C, Gottig S, Schilling S, Asper M, Panning M, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323–2330.
- Armitage P, Berry G, Matthews J. Statistical methods in medical research. 4 ed. Oxford: Blackwell Science; 2002.
- World Health Organization Expert Committee on Biological Standardization. 46th report. 1998. WHO Technical Report ser. No. 872. Geneva, World Health Organization.
- Monath TP. Yellow Fever Vaccine. Exp rev vaccines. 2005;4:553–574.
- Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Human Vaccin. 2005;1:106–111.
- Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998;56:159–167.
- Barba-Spaeth G, Longman RS, Albert ML, Rice CM. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med. 2005;202:1179–1184.
- Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol. 2007;88:148–156.
- WHO. 2007;82:153–160. Weekly epidemiological record. Assessment of yellow fever epidemic risk-a decision-making tool for preventive immunization campaigns. .
Source: PubMed